title: The next 10 years for tuberculosis vaccines: do we have the right plans in place?
abstract: The control of TB is a global health priority. Over the last decade, considerable progress has been made in the field of TB vaccines with numerous vaccine candidates entering the clinic and two candidates now in Phase IIb efficacy trials. Nevertheless, the lack of predictive animal models and biomarkers of TB vaccine efficacy prevents rational vaccine down-selection and necessitates prolonged and expensive clinical efficacy trials in target populations. Advances in molecular technology and progress in the development of human as well as animal mycobacterial challenge models make the identification of one or more immune correlates of protection a genuine prospect over the next decade. Moreover, the increasing pace, extent and coordination of global research efforts in TB promises to broaden understanding and inform the next generation of vaccine candidates against TB as well as related globally important pathogens.
authors.affiliation: The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
authors.forename: Joel
authors.initials: J
authors.lastname: Meyer
authors.forename: Helen
authors.initials: H
authors.lastname: McShane
mesh_terms: D000818:Animals; D015415:Biomarkers; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D014376:Tuberculosis / Q000453:epidemiology* / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D015415:Biomarkers; D032581:Tuberculosis Vaccines
references.citation: Clin Infect Dis. 2000 Jun;30 Suppl 3:S257-61
references.pmid: 10875795
references.citation: Vaccine. 2001 Oct 15;20 Suppl 1:S58-67
references.pmid: 11587814
references.citation: Tuberculosis (Edinb). 2012 Sep;92(5):440-4
references.pmid: 22658910
references.citation: Tuberculosis (Edinb). 2008 Nov;88(6):631-40
references.pmid: 18801705
references.citation: Nature. 1998 Jun 11;393(6685):537-44
references.pmid: 9634230
references.citation: Science. 2011 Dec 16;334(6062):1488-90
references.pmid: 22174226
references.citation: Am J Respir Crit Care Med. 2012 Apr 1;185(7):769-78
references.pmid: 22281831
references.citation: Nat Med. 2004 Nov;10(11):1240-4
references.pmid: 15502839
references.citation: Clin Infect Dis. 2010 May 15;50 Suppl 3:S178-83
references.pmid: 20397946
references.citation: Sci Transl Med. 2011 Jun 22;3(88):88ra56
references.pmid: 21697532
references.citation: Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5
references.pmid: 15831840
references.citation: Am J Trop Med Hyg. 2012 Apr;86(4):561-5
references.pmid: 22492136
references.citation: J Virol. 2007 May;81(9):4654-63
references.pmid: 17329340
references.citation: JAMA. 1998 May 13;279(18):1423-4
references.pmid: 9600461
references.citation: Clin Infect Dis. 2012 Jul;55(1):19-25
references.pmid: 22441650
references.citation: J Immunol. 1998 Mar 1;160(5):2408-17
references.pmid: 9498784
references.citation: Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38
references.pmid: 15687025
references.citation: Vaccine. 2006 Apr 24;24(17):3408-19
references.pmid: 16564606
references.citation: Eur J Immunol. 2007 Nov;37(11):3089-100
references.pmid: 17948267
references.citation: Vaccine. 2012 Aug 17;30(38):5616-24
references.pmid: 22789508
references.citation: Nat Med. 2010 Mar;16(3):339-45
references.pmid: 20139992
references.citation: J Infect Dis. 2012 Apr 1;205(7):1035-42
references.pmid: 22396610
references.citation: Mol Ther. 2012 Dec;20(12):2355-68
references.pmid: 23089736
references.citation: J Infect Dis. 2011 Nov 15;204(10):1573-84
references.pmid: 21933877
references.citation: Tuberculosis (Edinb). 2012 May;92(3):211-7
references.pmid: 22429719
references.citation: Vaccine. 2010 Apr 30;28(20):3571-81
references.pmid: 20226890
references.citation: Clin Infect Dis. 2000 Jun;30 Suppl 3:S233-42
references.pmid: 10875790
references.citation: Nature. 2010 Aug 19;466(7309):973-7
references.pmid: 20725040
references.citation: Lancet. 2009 Jun 20;373(9681):2113-24
references.pmid: 19541038
references.citation: Nat Immunol. 2009 Jan;10(1):116-125
references.pmid: 19029902
references.citation: Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9
references.pmid: 20558627
references.citation: J Infect Dis. 2001 Apr 15;183(8):1300-3
references.pmid: 11262217
references.citation: Lancet. 2012 Mar 24;379(9821):1077-8
references.pmid: 22444391
references.citation: Vaccine. 2013 Apr 19;31(17):2196-206
references.pmid: 22643213
references.citation: PLoS One. 2012;7(6):e39909
references.pmid: 22768165
references.citation: Proc R Soc Med. 1931 Sep;24(11):1481-90
references.pmid: 19988326
references.citation: BMJ Open. 2011 Nov 14;1(2):e000223
references.pmid: 22102640
references.citation: Tuberculosis (Edinb). 2011 Jul;91(4):329-38
references.pmid: 21478054
references.citation: J R Soc Interface. 2008 Jun 6;5(23):653-62
references.pmid: 17690054
references.citation: Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S6-13
references.pmid: 22441160
references.citation: PLoS One. 2009;4(4):e5264
references.pmid: 19367339
references.citation: Lancet Infect Dis. 2005 Oct;5(10):629-36
references.pmid: 16183517
references.citation: Nat Med. 2011 Sep 04;17(10):1261-8
references.pmid: 21892180
references.citation: Nat Med. 2011 Feb;17(2):189-94
references.pmid: 21258338
references.citation: Vaccine. 2011 May 17;29(22):3895-904
references.pmid: 21443963
references.citation: Infect Immun. 2004 Nov;72(11):6401-7
references.pmid: 15501770
references.citation: PLoS Med. 2008 Jul 1;5(7):e145
references.pmid: 18597551